Participants received therapy for 56 weeks, followed by a 26-week follow-up period
Critical for identifying prediabetes or insulin resistance, which affects how well GLP-1 medications work and what side effects you might experience
Regulators cannot verify whether a vial actually contains the ingredient named on the label, whether the stated concentration is accurate, or whether the substance was manufactured, stored and transported under the rigorous conditions required for sterile injectables
Glucagon, in conventional metabolic understanding, raises blood glucose
Take it seriously - it's a practical interaction-risk advisory specific to this category, not standard boilerplate
In parallel, the landscape of pharmacological therapies for T2DM and (to a lesser extent) obesity has expanded in recent decades with new classes of molecules coming into the market